论文部分内容阅读
目的分析干扰素治疗慢性丙型病毒性肝炎(慢丙肝)引起甲状腺功能(甲功)异常的特征及影响因素。方法选取初次治疗的慢丙肝患者212例,其中用干扰素治疗106例(治疗组),对照组为条件均衡的非干扰素治疗患者106例;每组均为男51例,女55例。比较两组甲功异常发生率及影响因素。结果两组发生甲功异常30例,治疗组与对照组分别为27例(25.5%)、3例(2.8%)(P<0.01);治疗组男性甲功异常发生率低于女性(15.7%vs.34.5%)(P<0.05)。治疗组甲状腺自身抗体阳性29例,甲功异常23例(79.3%);甲状腺自身抗体阴性77例,甲功异常4例(5.2%),差异有统计学意义(P<0.01)。治疗组治疗24周甲功异常3例(2.8%),治疗48周新发甲功异常24例(22.6%),差异有统计学意义(P<0.01)。两组甲功异常患者中,甲功减退(甲减)21例,甲功亢进(甲亢)9例。结论干扰素治疗慢丙肝可致甲状腺功能异常,女性易受影响,甲状腺自身抗体阳性者容易发生甲功异常,而且多在干扰素治疗后期出现。
Objective To analyze the characteristics and influencing factors of abnormal thyroid function (thyroid function) caused by interferon in the treatment of chronic hepatitis C (chronic hepatitis C). Methods A total of 212 patients with chronic hepatitis C who were treated for the first time were selected, of whom 106 were treated with interferon (treatment group), and 106 were non-interferon treated patients in the control group. Each group had 51 males and 55 females. The incidence and influencing factors of thyroid dysfunction in both groups were compared. Results There were 30 cases of abnormal thyroid function in both groups, 27 cases (25.5%) and 3 cases (2.8%) in the treatment group and the control group respectively (P <0.01). The incidence of abnormal thyroid function in the treatment group was lower than that in the female group (15.7% vs. 34.5%) (P <0.05). There were 29 cases with thyroid autoantibodies in the treatment group, 23 cases with abnormal thyroid function (79.3%), 77 cases with negative thyroid autoantibodies, and 4 cases with abnormal thyroid function (5.2%). The difference was statistically significant (P <0.01). The treatment group had 24 cases of abnormal thyroid function at 24 weeks (2.8%), and 24 cases (22.6%) of newly developed abnormal thyroid function at 48 weeks after treatment. The difference was statistically significant (P <0.01). Of the two patients with abnormal thyroid function, hypothyroidism (hypothyroidism) in 21 cases, hyperthyroidism (hyperthyroidism) in 9 cases. Conclusion Interferon treatment of chronic hepatitis C can cause thyroid dysfunction, women vulnerable, thyroid autoantibodies are prone to abnormal thyroid function, and more in the late stage of interferon treatment.